Ratings by Raymond James (Timur Ivannikov)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 5/5/2023 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 5/5/2023 | Kymera Therapeutics | KYMR | Upgrade | Outperform (Market Perform) |
30.90 (123.08) |
298.32% | Details | |
| 3/7/2023 | Gossamer Bio Inc. | GOSS | Downgrade | Market Perform (Outperform) |
1.83 (0.16) |
-91.26% | Details | |
| 1/6/2023 | AnaptysBio | ANAB | Downgrade | Market Perform (Outperform) |
29.19 (57.80) |
98.01% | Details | |
| 11/17/2022 | Gossamer Bio Inc. | GOSS | Maintain | Outperform (N/A) |
|
Details | ||
| 11/15/2022 | NexImmune Inc | NEXI | Downgrade | Market Perform (Outperform) |
0.49 (3.93) |
702.04% | Details | |
| 11/11/2022 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/9/2022 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2022 | Kymera Therapeutics | KYMR | New Coverage | Market Perform (N/A) |
29.04 (123.08) |
323.83% | Details | |
| 9/1/2022 | AnaptysBio | ANAB | New Coverage | Outperform (N/A) |
23.76 (57.80) |
143.27% | Details | |
| 8/16/2022 | NexImmune Inc | NEXI | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2022 | Rocket Pharmaceuticals | RCKT | Maintain | Outperform (N/A) |
|
Details | ||
| 7/13/2022 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 7/8/2022 | Rocket Pharmaceuticals | RCKT | New Coverage | Outperform (N/A) |
16.15 (3.56) |
-77.96% | Details | |
| 4/18/2022 | Gossamer Bio | KOSS | New Coverage | Outperform (N/A) |
7.46 (3.56) |
-52.28% | Details | |
| 11/15/2021 | NexImmune Inc | NEXI | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2021 | Catalyst Biosciences | CBIO | Downgrade | Market Perform (Outperform) |
2.94 (16.67) |
467.01% | Details | |
| 9/13/2021 | Leap Therapeutics | LPTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2021 | NexImmune Inc | NEXI | New Coverage | Outperform (N/A) |
18.32 (3.93) |
-78.55% | Details |
